A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice

The EMBL-EBI search and sequence analysis tools APIs in 2019

Madeira, F., Park, Y. M., Lee, J., Buso, N., Gur, T., Madhusoodanan, N., Basutkar, P., Tivey, A. R. N., Potter, S. C., Finn, R. D., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz268 · Cited by 4,167

Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA

Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728

Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis

Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789

Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes

Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014

The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses

Hobson, D., Curry, R. L., Beare, A. S., & Ward-Gardner, A. (1972) · Epidemiology and Infection · doi:10.1017/s0022172400022610 · Cited by 1,003

Modified mRNA vaccines protect against zika virus infection

Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909

Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination

Pardi, N., Hogan, M. J., Pelc, R. S., Muramatsu, H., Andersen, H., DeMaso, C. R., Dowd, K. A., Sutherland, L. L., Scearce, R. M., Parks, R., et al. (2017) · Nature · doi:10.1038/nature21428 · Cited by 884

Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection

Yassine, H. M., Boyington, J. C., McTamney, P. M., Wei, C., Kanekiyo, M., Kong, W., Gallagher, J. R., Wang, L., Zhang, Y., Joyce, M. G., et al. (2015) · Nature Medicine · doi:10.1038/nm.3927 · Cited by 700

Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses

Bahl, K., Senn, J. J., Yuzhakov, O., Bulychev, A., Brito, L. A., Hassett, K. J., Laska, M. E., Smith, M., Almarsson, Ö., Thompson, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.035 · Cited by 642

Advances in the development of influenza virus vaccines

Krammer, F., & Palese, P. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4529 · Cited by 592

Tick immunity using mRNA, DNA and protein-based Salp14 delivery strategies

Matias, J., Kurokawa, C., Sajid, A., Narasimhan, S., Arora, G., Diktaş, H., Lynn, G. E., DePonte, K., Pardi, N., Valenzuela, J. G., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.11.003 · Cited by 38

mRNA vaccines against respiratory viruses

Whitaker, J. A., Sahly, H. M. E., & Healy, C. M. (2023) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000948 · Cited by 39

A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax

Kunkeaw, N., Nguitragool, W., Takashima, E., Kangwanrangsan, N., Muramatsu, H., Tachibana, M., Ishino, T., Lin, P. J. C., Tam, Y. K., Pichyangkul, S., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00786-9 · Cited by 34

Promising Adjuvants and Platforms for Influenza Vaccine Development

Zhu, W., Dong, C., Wei, L., & Wang, B. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010068 · Cited by 34

Immunogenicity and protective efficacy of SARS-CoV-2 mRNA vaccine encoding secreted non-stabilized spike in female mice

Prompetchara, E., Ketloy, C., Alameh, M., Tharakhet, K., Kaewpang, P., Yostrerat, N., Pitakpolrat, P., Buranapraditkun, S., Manopwisedjaroen, S., Thitithanyanont, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37795-0 · Cited by 31

Animal Models Utilized for the Development of Influenza Virus Vaccines

Roubidoux, E. K., & Schultz‐Cherry, S. (2021) · Vaccines · doi:10.3390/vaccines9070787 · Cited by 31

Advances in mRNA and other vaccines against MERS-CoV

Tai, W., Zhang, X., Yang, Y., Zhu, J., & Du, L. (2021) · Translational research · doi:10.1016/j.trsl.2021.11.007 · Cited by 36

Lipid-Based Delivery Systems in Development of Genetic and Subunit Vaccines

Bolhassani, A. (2022) · Molecular Biotechnology · doi:10.1007/s12033-022-00624-8 · Cited by 36

The Potential of Neuraminidase as an Antigen for Nasal Vaccines To Increase Cross-Protection against Influenza Viruses

Kawai, A., Yamamoto, Y., Nogimori, T., Takeshita, K., Yamamoto, T., & Yoshioka, Y. (2021) · Journal of Virology · doi:10.1128/jvi.01180-21 · Cited by 31

A single vaccination of nucleoside-modified Rabies mRNA vaccine induces prolonged highly protective immune responses in mice

Bai, S., Yang, T., Zhu, C., Feng, M., Zhang, L., Zhang, Z., Wang, X., Yu, R., Pan, X., Chen, Z., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1099991 · Cited by 31

What should be the baseline when calculating excess mortality? New approaches suggest that we have underestimated the impact of the COVID-19 pandemic and previous winter peaks

Школьников, В. М., Klimkin, I., McKee, M., Jdanov, D. A., Galarza, A. A., Németh, L., Тимонин, С. А., Nepomuceno, M. R., Андреев, Е. М., & Leon, D. A. (2022) · SSM - Population Health · doi:10.1016/j.ssmph.2022.101118 · Cited by 29

Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals

Lederer, K., Parvathaneni, K., Painter, M. M., Bettini, E., Agarwal, D., Lundgreen, K. A., Weirick, M., Goel, R. R., Xu, X., Drapeau, E. M., et al. (2021) · doi:10.1101/2021.09.16.21263686 · Cited by 179

mRNA vaccines: A novel weapon to control infectious diseases

Tian, Y., Deng, Z., & Yang, P. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1008684 · Cited by 29

Advances in nanomedicine for the treatment of infectious diseases caused by viruses

Dash, S. R., & Kundu, C. N. (2023) · Biomaterials Science · doi:10.1039/d2bm02066a · Cited by 29

mRNA, the beginning of a new influenza vaccine game

Pecetta, S., & Rappuoli, R. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2217533119 · Cited by 28

Cryptic MHC-E epitope from influenza elicits a potent cytolytic T cell response

Hogan, M. J., Maheshwari, N., Begg, B. E., Nicastri, A., Hedgepeth, E. J., Muramatsu, H., Pardi, N., Miller, M. A., Reilly, S. P., Brossay, L., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01644-5 · Cited by 28

Improved influenza vaccine responses after expression of multiple viral glycoproteins from a single mRNA

Leonard, R. A., Burke, K. N., Spreng, R. L., Macintyre, A. N., Tam, Y. K., Alameh, M., Weissman, D., & Heaton, N. S. (2024) · Nature Communications · doi:10.1038/s41467-024-52940-z · Cited by 27

mRNA therapeutics: Transforming medicine through innovation in design, delivery, and disease treatment

Ige, M. A., Ren, X., Yang, Y., Zhang, H., Shen, C., Jiang, Y., Li, J., & Wan, X. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102721 · Cited by 30

Restoration of Motor Function through Delayed Intraspinal Delivery of Human IL-10-Encoding Nucleoside-Modified mRNA after Spinal Cord Injury

Gál, L., Bellák, T., Marton, A., Fekécs, Z., Weissman, D., Török, D. G., Biju, R., Vízler, C., Kristóf, R., Beattie, M. B., et al. (2023) · Research · doi:10.34133/research.0056 · Cited by 26

Neuraminidase delivered as an APC-targeted DNA vaccine induces protective antibodies against influenza

Werninghaus, I. C., Hinke, D. M., Fossum, E., Bogen, B., & Braathen, R. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.03.012 · Cited by 26

Fc‐ FcγR interactions during infections: From neutralizing antibodies to antibody‐dependent enhancement

Edgar, J. E., & Bournazos, S. (2024) · Immunological Reviews · doi:10.1111/imr.13393 · Cited by 32

Universal Flu mRNA Vaccine: Promises, Prospects, and Problems

Deviatkin, A. A., Simonov, R. A., Trutneva, K. A., Maznina, A. A., Khavina, E. M., & Volchkov, P. (2022) · Vaccines · doi:10.3390/vaccines10050709 · Cited by 26

Advances in nanoparticle-based mRNA delivery for liver cancer and liver-associated infectious diseases

Chung, S., Lee, C. M., & Zhang, M. (2022) · Nanoscale Horizons · doi:10.1039/d2nh00289b · Cited by 28

Nucleoprotein as a Promising Antigen for Broadly Protective Influenza Vaccines

Rak, A. Y., Николаевна, И.-С. И., & Георгиевна, Р. Л. (2023) · Vaccines · doi:10.3390/vaccines11121747 · Cited by 25

Anti-Influenza Strategies Based on Nanoparticle Applications

Wieczorek, K., Szutkowska, B., & Kierzek, E. (2020) · Pathogens · doi:10.3390/pathogens9121020 · Cited by 24

Strategies for eliciting multiple lineages of broadly neutralizing antibodies to HIV by vaccination

Mu, Z., Haynes, B. F., & Cain, D. W. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.09.015 · Cited by 23

Multiplexed LNP-mRNA vaccination against pathogenic coronavirus species

Peng, L., Fang, Z., Renauer, P. A., McNamara, A., Park, J. J.-Y., Lin, Q., Zhou, X., Dong, M. B., Zhu, B., Zhao, H., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111160 · Cited by 26

Computationally designed mRNA-launched protein nanoparticle immunogens elicit protective antibody and T cell responses in mice

Hendricks, G. G., Grigoryan, L., Navarro, M. J., Catanzaro, N., Hubbard, M. L., Powers, J. M., Mattocks, M. D., Treichel, C., Walls, A. C., Lee, J., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adu2085 · Cited by 24

mRNA delivery technologies: Toward clinical translation

Gómez-Aguado, I., Rodríguez-Castejón, J., Beraza-Millor, M., Rodríguez‐Gascón, A., del Pozo‐Rodríguez, A., & Solinís, M. Á. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.010 · Cited by 23

Nanoparticle-based delivery platforms for mRNA vaccine development

Okay, S., Özcan, Ö. Ö., & Karahan, M. (2020) · AIMS Biophysics · doi:10.3934/biophy.2020023 · Cited by 23

The mRNA vaccine, a swift warhead against a moving infectious disease target

Mir, S., & Mir, M. A. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2320327 · Cited by 28

Researchers getting closer to a “universal” flu vaccine

Beans, C. M. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2123477119 · Cited by 22

Contribution of Neuraminidase to the Efficacy of Seasonal Split Influenza Vaccines in the Ferret Model

Rosu, M. E., Kok, A., Bestebroer, T. M., de Meulder, D., Verveer, E. P., Pronk, M., Dekker, L. J. M., Luider, T. M., Richard, M., van den Brand, J. M. A., et al. (2022) · Journal of Virology · doi:10.1128/jvi.01959-21 · Cited by 21

Safety, Immunogenicity, and Mechanism of a Rotavirus mRNA-LNP Vaccine in Mice

Lu, C., Li, Y., Chen, R., Hu, X., Leng, Q., Song, X., Lin, X., Ye, J., Wang, J., Li, J., et al. (2024) · Viruses · doi:10.3390/v16020211 · Cited by 19

Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response

Mazunina, E. P., Gushchin, V. А., Kleymenov, D. A., Siniavin, A. E., Ei, B., Шмаров, М. М., Мукашева, Е. А., Bykonia, E. N., Kozlova, S. R., Evgrafova, E. A., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1381508 · Cited by 19

Separation of long-stranded RNAs by RP-HPLC using an octadecyl-based column with super-wide pores

Kuwayama, T., Ozaki, M., Shimotsuma, M., & Hirose, T. (2022) · Analytical Sciences · doi:10.1007/s44211-022-00253-w · Cited by 19

Lipid Nanocarrier‐Based mRNA Therapy: Challenges and Promise for Clinical Transformation

Li, W., Wang, C., Zhang, Y., & Lu, Y. (2024) · Small · doi:10.1002/smll.202310531 · Cited by 21

A chimeric haemagglutinin-based universal influenza virus vaccine boosts human cellular immune responses directed towards the conserved haemagglutinin stalk domain and the viral nucleoprotein

Bliss, C. M., Nachbagauer, R., Mariottini, C., Cuevas, F., Feser, J., Naficy, A., Bernstein, D. I., Guptill, J. T., Walter, E. B., Scorza, F. B., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105153 · Cited by 19

Influence of salt solution on the physicochemical properties and in vitro/ in vivo expression of mRNA/LNP

Tang, S., Huang, L., Ge, J., Li, J., Qiu, M., Zhang, Y., Long, M., Wu, G., Zhang, R., Ma, X., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03318-w · Cited by 19

mRNA Vaccines: Current Applications and Future Directions

Li, J., Liu, Y., Dai, J., Li, Y., Xiong, F., Xia, J., Jin, J., Wu, Y., & Peng, X. (2025) · MedComm · doi:10.1002/mco2.70434 · Cited by 27

A new H9 influenza virus mRNA vaccine elicits robust protective immunity against infection

Xu, S., Zhang, B., Yao, J., & Ruan, W. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.03.049 · Cited by 18

Polyplex nanomicelle delivery of self-amplifying RNA vaccine

Chang, Y., Lin, M., Chien, M.-C., Ke, G., Wu, I.-E., Lin, R.-L., Lin, C., & Hu, Y. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.09.008 · Cited by 18

Bioengineering Strategies for Developing Vaccines against Respiratory Viral Diseases

Iyer, S., Yadav, R. T., Agarwal, S., Tripathi, S., & Agarwal, R. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00123-21 · Cited by 20

Development of an mRNA vaccine against a panel of heterologous H1N1 seasonal influenza viruses using a consensus hemagglutinin sequence

Ma, N., Xia, Z.-W., Zhang, Z., Nian, X., Li, X.-D., Gong, Z., Zhang, G., Yang, L., Zhou, R., Zhang, J., et al. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2202278 · Cited by 18

Specific mRNA lipid nanoparticles and acquired resistance to ticks

Matias, J., Cui, Y., Tang, X., Sajid, A., Arora, G., Wu, M.-J., DePonte, K., Muramatsu, H., Tam, Y. K., Narasimhan, S., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.06.081 · Cited by 17

Avian influenza mRNA vaccine encoding hemagglutinin provides complete protection against divergent H5N1 viruses in specific-pathogen-free chickens

Wang, Z., Tian, C., Zhu, J., Wang, S., Ao, X., He, Y., Chen, H., Liao, X., Kong, D., Zhou, Y.-F., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03156-w · Cited by 18

The self-assembled nanoparticle-based multi-epitope influenza mRNA vaccine elicits protective immunity against H1N1 and B influenza viruses in mice

Di, Y., Zhang, C., Ren, Z., Jiang, R., Tang, J., Yang, S., Wang, Z., Yu, T., Zhang, T., Yu, Z., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1483720 · Cited by 17

Promising strategy for developing mRNA-based universal influenza virus vaccine for human population, poultry, and pigs– focus on the bigger picture

Rcheulishvili, N., Papukashvili, D., Liu, C., Ji, Y., He, Y., & Wang, P. G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1025884 · Cited by 17

Protective efficacy of a universal influenza mRNA vaccine against the challenge of H1 and H5 influenza A viruses in mice

Li, Y., Wang, X., Zeng, X., Ren, W., Liao, P., & Zhu, B. (2023) · mLife · doi:10.1002/mlf2.12085 · Cited by 16

Characterization of humoral and cell-mediated immunity induced by mRNA vaccines expressing influenza hemagglutinin stem and nucleoprotein in mice and nonhuman primates

Flynn, J. A., Weber, T., Cejas, P. J., Cox, K. S., Touch, S., Austin, L. A., Ou, Y., Citron, M. P., Luo, B., Gindy, M. E., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.03.063 · Cited by 16

Nucleoside-Modified mRNA-Based Influenza Vaccines Circumvent Problems Associated with H3N2 Vaccine Strain Egg Adaptation

Gouma, S., Furey, C., Santos, J. J. D. S., Parkhouse, K., Weirick, M. E., Muramatsu, H., Pardi, N., Fan, S. H. Y., Weissman, D., & Hensley, S. E. (2022) · Journal of Virology · doi:10.1128/jvi.01723-22 · Cited by 16

Nanobiotechnology-Enabled mRNA Stabilization

Xian, H., Zhang, Y., Yu, C., & Wang, Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020620 · Cited by 19

The Impact of mRNA Technology in Regenerative Therapy: Lessons for Oral Tissue Regeneration

Wisitrasameewong, W., Champaiboon, C., Surisaeng, T., Sa‐Ard‐Iam, N., Freire, M., Pardi, N., Pichyangkul, S., & Mahanonda, R. (2022) · Journal of Dental Research · doi:10.1177/00220345221084205 · Cited by 15

Nanovaccines to combat drug resistance: the next-generation immunisation

Manju, K., Raj, S. N., Ranjini, H. K., Nayaka, S. C., Ashwini, P., Satish, S., Prasad, M. N. N., Chouhan, R. S., & Baker, S. (2023) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-023-00515-y · Cited by 16

Development and efficacy of a novel mRNA cocktail for the delivery of African swine fever virus antigens and induction of immune responses

Hu, X., Liu, C., Rcheulishvili, N., Wang, Y., Xiong, T., Xie, F., Wang, X., Chen, R., Wang, P. G., & He, Y. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.02909-24 · Cited by 14

Intranasal hemagglutinin protein boosters induce protective mucosal immunity against influenza A viruses in mice

Moriyama, M., Rodrigues, G. R., Wang, J., Jayewickreme, R., Hudak, A., Dong, H., Homer, R., Ma, S., & Iwasaki, A. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2422171122 · Cited by 21

Molecular engineering tools for the development of vaccines against infectious diseases: current status and future directions

Xue, W., Li, T., Gu, Y., Li, S., & Xia, N. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2227699 · Cited by 19

Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review

Belay, W. Y., Nibret, G., & Aschale, Y. (2023) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s418314 · Cited by 16

Sequential vaccinations with divergent H1N1 influenza virus strains induce multi-H1 clade neutralizing antibodies in swine

Reeth, K. V., Parys, A., Gracia, J. C. M., Trus, I., Chiers, K., Meade, P. S., Liu, S. T. H., Palese, P., Krammer, F., & Vandoorn, E. (2023) · Nature Communications · doi:10.1038/s41467-023-43339-3 · Cited by 14

Message in a bottle: mRNA vaccination for influenza

Shartouny, J. R., & Lowen, A. C. (2022) · Journal of General Virology · doi:10.1099/jgv.0.001765 · Cited by 15

Agent-based model of the impact of higher influenza vaccine efficacy on seasonal influenza burden

Krauland, M. G., Zimmerman, R. K., Williams, K. V., Raviotta, J. M., Harrison, L. H., Williams, J. V., & Roberts, M. S. (2022) · Vaccine X · doi:10.1016/j.jvacx.2022.100249 · Cited by 12

Advances in Nucleic Acid Universal Influenza Vaccines

Xu, L., Ren, W., Wang, Q., & Li, J. (2024) · Vaccines · doi:10.3390/vaccines12060664 · Cited by 13

Nanoparticles and Nanomaterials: A Review from the Standpoint of Pharmacy and Medicine

Petrov, G. V., Koldina, A. M., Ledenev, O. V., Tumasov, V. N., Nazarov, A. V., & Syroeshkin, A. V. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17050655 · Cited by 14

Delivery strategies for RNA-targeting therapeutic nucleic acids and RNA-based vaccines against respiratory RNA viruses: IAV, SARS-CoV-2, RSV

Maziec, K., Baliga-Gil, A., & Kierzek, E. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102572 · Cited by 15

mRNA therapeutics beyond vaccines: dosing precision challenges and clinical translation framework

Niazi, S. K. (2025) · RSC Pharmaceutics · doi:10.1039/d5pm00159e · Cited by 12

mRNA-LNP vaccine-induced CD8+ T cells protect mice from lethal SARS-CoV-2 infection in the absence of specific antibodies

Montoya, B., Melo‐Silva, C. R., Tang, L., Kafle, S., Lidskiy, P., Bajusz, C., Vadovics, M., Muramatsu, H., Ábrahám, E., Lipinszki, Z., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.04.019 · Cited by 14

Improving cross-protection against influenza virus in mice using a nanoparticle vaccine of mini-HA

Zhu, H., Li, X., Ren, X., Chen, H., & Qian, P. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.09.058 · Cited by 12

Targets of protective immunity and opportunities in hepatitis C virus vaccine development

Park, S. B., Zimmer-Harwood, P., & Liang, T. J. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01215-9 · Cited by 11

Rapid Identity and Quantity CQA Test for Multivalent mRNA Drug Product Formulations

Gao, R. Y., Riley, C. M., Toth, E., Blair, R. H., Gerold, M. N., McCormick, C., Taylor, A. W., Hu, T., Rowlen, K. L., & Dawson, E. D. (2022) · Vaccines · doi:10.3390/vaccines10101704 · Cited by 12

A combination influenza mRNA vaccine candidate provided broad protection against diverse influenza virus challenge

Tian, Y., Deng, Z., Chuai, Z., Li, C., Chang, L., Sun, F., Cao, R., Yu, H., Xiao, R., Lü, S., et al. (2024) · Virology · doi:10.1016/j.virol.2024.110125 · Cited by 15

Influenza 5xM2e mRNA lipid nanoparticle vaccine confers broad immunity and significantly enhances the efficacy of inactivated split vaccination when coadministered

Grovenstein, P. B., Bhatnagar, N., Kim, K., Pal, S. S., Le, C. T. T., Raha, J. R., Liu, R., Shin, C. H., Park, B. R., Du, L., et al. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkae013 · Cited by 11

iDC-targeting PfCSP mRNA vaccine confers superior protection against Plasmodium compared to conventional mRNA

Yanik, S. A., Venkatesh, V., Gordy, J. T., Alameh, M., Meza, J., Li, Y., Glass, E., Flores-García, Y., Tam, Y. K., Chaiyawong, N., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01089-x · Cited by 11

Rational Design and Immunological Mechanisms of Circular RNA-Based Vaccines: Emerging Frontiers in Combating Pathogen Infection

Zhang, Y., Jin, S., Zuo, Z., Liu, S., Xu, J., Yang, C., Wan, P., Xun, L., Luo, M., Yang, F., et al. (2025) · Vaccines · doi:10.3390/vaccines13060563 · Cited by 10

Deciphering immune responses: a comparative analysis of influenza vaccination platforms

Jones, C. H., Hauguel, T., Beitelshees, M., Davitt, M., Welch, V., LINDERT, K. A., Allen, P. S., True, J. M., & Dolsten, M. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104125 · Cited by 12

Exploring in vitro expression and immune potency in mice using mRNA encoding the Plasmodium falciparum malaria antigen, CelTOS

Waghela, I. N., Mallory, K. L., Taylor, J. A., Schneider, C. G., Savransky, T., Janse, C. J., Lin, P. J. C., Tam, Y. K., Weissman, D., & Angov, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1026052 · Cited by 10

Humoral Response to the Acetalated Dextran M2e Vaccine is Enhanced by Antigen Surface Conjugation

Batty, C. J., Pena, E. S., Amouzougan, E. A., Moore, K. M., Ainslie, K. M., & Bachelder, E. M. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00223 · Cited by 10

Distinct components of nucleoside-modified messenger RNA vaccines cooperate to instruct efficient germinal center responsesPreprint

Bettini, E., Chudnovskiy, A., Protti, G., Nakandakari-Higa, S., Ceglia, S., Castaño, D., Chiu, J. E., Muramatsu, H., Mdluli, T., Ábrahám, E., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.17.594726 · Cited by 10

Influenza vaccines: where we are, where we are going.

Khalil, N., & Bernstein, D. I. (2022) · PubMed · doi:10.1097/mop.0000000000001103 · Cited by 9

Identification of a seasonal influenza vaccine–induced broadly protective neuraminidase antibody

Madsen, A., Okba, N. M. A., Pholcharee, T., Matz, H. C., Lv, H., Trullen, M. I., Zhou, J. Q., Turner, J. S., Schmitz, A. J., Han, F., et al. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20241930 · Cited by 9

Advances in Infectious Bursal Disease Virus Vaccines—A Review

Wang, W., Wu, J., Jiang, N., Liang, Q., Liu, R., Fu, Q., Fu, G., Wei, T., Wan, C., Cheng, L., et al. (2025) · Microorganisms · doi:10.3390/microorganisms13122801 · Cited by 9

Elements of Viral Outbreak Preparedness: Lessons, Strategies, and Future Directions

Hamza, I. A., Mao, K., Gao, C., Hamza, H., & Zhang, H. (2025) · Viruses · doi:10.3390/v18010050 · Cited by 11

La nueva generación de vacunas de ARN mensajero (ARNm) frente a la gripe

Reina, J. (2021) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2021.07.009 · Cited by 11

Emerging trends of research on mRNA vaccines: A co-citation analysis

Chen, J., Zhang, T., Lu, Y. Z., Yang, X., & Ouyang, Z. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2110409 · Cited by 10

The new generation of messenger RNA (mRNA) vaccines against influenza

Reina, J. (2022) · Enfermedades infecciosas y microbiologia clinica (English ed ) · doi:10.1016/j.eimce.2022.07.006 · Cited by 10

Harnessing the Potential of mRNA Vaccines Against Infectious Diseases

Rezk, N., & McClean, S. (2025) · Microbial Biotechnology · doi:10.1111/1751-7915.70212 · Cited by 10

mRNA vaccine developed for sequential selective organ-to-cell targeting of glioma

Lin, S., Li, Y., Huang, S., Peng, J., Liu, C., Hu, Z., Deng, W., & Deng, G. (2025) · Nature Communications · doi:10.1038/s41467-025-67331-1 · Cited by 9

Regional characteristics of influenza seasonality patterns in mainland China, 2005-2017: a statistical modeling study

Deng, X., Chen, Z., Zhao, Z., Chen, J., Li, M., Yang, J., & Yu, H. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.12.026 · Cited by 8

Inactivated influenza virions are a flexible vaccine platform for eliciting protective antibody responses against neuraminidase

Martinez, M. R., Gao, J., Wan, H., Kang, H., Klenow, L., & Daniels, R. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.05.068 · Cited by 8

Cellular and Molecular Immunity to Influenza Viruses and Vaccines

Kasten‐Jolly, J., & Lawrence, D. A. (2024) · Vaccines · doi:10.3390/vaccines12040389 · Cited by 8

Analytical Performance of a Multiplexed Microarray Assay for Rapid Identification and Quantification of a Multivalent mRNA Vaccine

Gerold, M. N., Toth, E., Blair, R. H., Gao, R. Y., Nadkarni, D. V., Barua, S., Woods, J., Rowlen, K. L., & Dawson, E. D. (2024) · Vaccines · doi:10.3390/vaccines12101144 · Cited by 8

Immunogenicity and Efficacy of Combined mRNA Vaccine Against Influenza and SARS-CoV-2 in Mice Animal Models

Mazunina, E. P., Gushchin, V. А., Bykonia, E. N., Kleymenov, D. A., Siniavin, A. E., Kozlova, S. R., Мукашева, Е. А., Shidlovskaya, E. V., Kuznetsova, N. A., Usachev, E. V., et al. (2024) · Vaccines · doi:10.3390/vaccines12111206 · Cited by 9

A minimally-edited mouse model for infection with multiple SARS-CoV-2 strains

Nakandakari-Higa, S., Parsa, R., Reis, B. S., de Carvalho, R. A., Mesin, L., Hoffmann, H.-H., Bortolatto, J., Muramatsu, H., Lin, P. J. C., Bilate, A. M. B., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1007080 · Cited by 8

DDO-adjuvanted influenza A virus nucleoprotein mRNA vaccine induces robust humoral and cellular type 1 immune responses and protects mice from challenge

Gnazzo, V., Saleh, H., Castro, Í. A., Boon, A. C. M., Pinto, A. K., Brien, J. D., & López, C. B. (2024) · mBio · doi:10.1128/mbio.03589-24 · Cited by 7

Reverse vaccinology-based design of multivalent multiepitope mRNA vaccines targeting key viral proteins of Herpes Simplex Virus type-2

Suneesh, N. S., Dhotre, K., Mahajan, P., Dass, D., Banerjee, A., Siddiqi, N. J., Malik, A., Joshi, M., Khan, A. A., Nema, V., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1586271 · Cited by 7

Chimeric hemagglutinin and M2 mRNA vaccine for broad influenza subtype protection

Yi, D., Liu, Q., Guo, S., Li, Q., Zhang, Y., Li, N., Zhang, Q., Lv, K., An, N. A., Han, L., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01178-x · Cited by 7

Immunotherapy against colorectal cancer via delivery of anti-PD-L1 nanobody mRNA

Chu, W., Ma, L., Hew, B. E., Sugawara, A., Wengrill, R., Guarary, A., Irei, J. S., Chan, O. T. M., Wang, J., Muramtsu, H., et al. (2025) · eGastroenterology · doi:10.1136/egastro-2024-100106 · Cited by 10

Preparing for Pandemics: RNA Vaccines at the Forefront

Erasmus, J. H., & FULLER, D. H. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.017 · Cited by 7

A systematic and thematic analysis of the top 100 cited articles on mRNA vaccine indexed in Scopus database

Musa, H. H., & Musa, T. H. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2135927 · Cited by 11

Innovative translational platforms for rapid developing clinical vaccines against COVID‐19 and other infectious disease

Wang, N., & Wang, T. (2024) · Biotechnology Journal · doi:10.1002/biot.202300658 · Cited by 11

Single-Cell Analysis of Antigen-Specific CD8+ T-Cell Transcripts Reveals Profiles Specific to mRNA or Adjuvanted Protein Vaccines

Meldgaard, T. S., Blengio, F., Maffione, D., Sammicheli, C., Tavarini, S., Nuti, S., Kratzer, R., Medini, D., Siena, E., & Bertholet, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.757151 · Cited by 7

Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses

Pardi, N., Carreño, J. M., O’Dell, G., Tan, J., Bajusz, C., Muramatsu, H., Rijnink, W. F., Strohmeier, S., Loganathan, M., Bielak, D. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32149-8 · Cited by 87

Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses

McMahon, M., O’Dell, G., Tan, J., Sárközy, A., Vadovics, M., Carreño, J. M., Puente‐Massaguer, E., Muramatsu, H., Bajusz, C., Rijnink, W. F., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2206333119 · Cited by 81

Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies

Pardi, N., Parkhouse, K., Kirkpatrick, E., McMahon, M., Zost, S. J., Mui, B. L., Tam, Y. K., Karikó, K., Barbosa, C. J., Madden, T. D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05482-0 · Cited by 281

A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes

Arevalo, C. P., Bolton, M. J., Sage, V. L., Ye, N., Furey, C., Muramatsu, H., Alameh, M., Pardi, N., Drapeau, E. M., Parkhouse, K., et al. (2022) · Science · doi:10.1126/science.abm0271 · Cited by 359

The self-assembled nanoparticle-based multi-epitope influenza mRNA vaccine elicits protective immunity against H1N1 and B influenza viruses in mice

Di, Y., Zhang, C., Ren, Z., Jiang, R., Tang, J., Yang, S., Wang, Z., Yu, T., Zhang, T., Yu, Z., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1483720 · Cited by 17